Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial.
Heikki HyötySusanna KääriäinenJutta E LaihoGail M ComerWei TianTaina HärkönenJussi P LehtonenSami OikarinenLeena PuustinenMichele SnyderFrancisco LeónMika ScheininOlli H LaitinenMiguel SanjuanPublished in: Diabetologia (2024)
This trial was funded by Provention Bio, a Sanofi company.